Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Single-centre, Double-blind, 2-period Cross-over Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus

Next Previous
Trial Profile

A Randomized, Single-centre, Double-blind, 2-period Cross-over Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin lispro/pramlintide (Primary) ; Insulin aspart
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacokinetics; Proof of concept
  • Sponsors Adocia

Most Recent Events

  • 22 Sep 2021 According to an Adocia media release, data from this study will be presented at the 57th Annual Meeting of the European Association for the Study of Diabetes (EASD).
  • 29 Jun 2021 Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association
  • 15 Jun 2021 According to an Adocia media release, the company will have an oral presentation on the bi-hormonal treatment M1Pram (ADO09) at the 81st Scientific Sessions of the American Diabetes Association.In this oral presentation, Gregory Meiffren, Clinical Development Director at Adocia will present this study and its key results.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top